Marksans Pharma Ltd — earnings calls

Marksans Pharma reported Q1 FY27 revenue of INR841 crores, up 35.6% year-on-year, with EBITDA of INR213 crores and PAT of INR159 crores, both described as the highest ever quarterly figures. UK and Europe revenue grew 74.7% year-on-year to INR356 crores, aided by the QliniQ acquisition, while North America grew 15.1% and Australia and New Zealand grew 53.7%. Management discussed the QliniQ and ABCnow acquisitions, gross margin drivers, working capital improvement, and plans for further expansion in Europe.

Marksans Pharma reported Q4 FY26 operating revenue of Rs 856 crores, up 20.8% year-on-year, with EBITDA margin expanding to 22.8% and profit after tax rising 64.3% to Rs 149 crores. For the full year, revenue crossed Rs 3,000 crores for the first time, reaching Rs 2,951 crores, with EBITDA margin at 20.4% and a year-end cash balance of Rs 990 crores. Management discussed raw material cost inflation linked to petroleum-related inputs and geopolitical disruption, alongside growth across North America, U.K., and Australia markets and new market entries in Germany, Canada and Ireland.